Nomura to buy Macquarie's US, European asset management units for US$1.8 billion
Japan's largest investment bank and brokerage will take over the management of the publicly traded assets, the companies said on Tuesday. It will also take over the investment teams and operating platforms relating to the businesses, and retain the existing management team.
The Japanese company has had a troubled history in its attempts to expand overseas, including the acquisition of assets from the collapsed Lehman Brothers in 2008 which it later wrote down.
But the Macquarie assets deal, which Nomura said is its largest acquisition ever, comes as companies in Japan face a shrinking domestic market and are increasingly seeking growth opportunities abroad.
Asset management has become a core growth area for Japanese financial institutions looking to secure stable fee-based revenue that is less impacted by the ups and downs of market sentiment.
"The market now is very unstable but the biggest factor in our mid to long term plan is to have a robust investment management platform," Nomura chief executive Kentaro Okuda told a press conference.
"This transaction had a very prudent due diligence process and should be durable against the volatility of the market," Okuda added.
The announcement of tariffs by US President Donald Trump may lead to a rebalancing of sectors which would provide opportunities for active investment managers, Nomura's head of investment management, Yoshihiro Namura, told the briefing.
The deal is expected to close by the end of 2025 and will be settled entirely by cash with no financing directly related to the transaction planned, Okuda said.
Nomura's previous investments include buying boutique investment bank Greentech Capital Advisors in 2019 and acquiring a 41 percent stake in investment management firm American Century Investments for over US$1 billion in 2016.
Upon the deal's completion, Nomura's total assets under management within its investment management franchise are expected to increase to around US$770 billion from approximately US$590 billion currently, Nomura said.
Nomura's shares climbed 0.6 percent on Tuesday morning while the benchmark Nikkei index was roughly flat. Macquarie shares rose around 1.5 percent.
Macquarie Group, Australia's biggest investment bank by assets, will retain its public investments business in its domestic market, where it plans to continue operating an asset management business spanning both public and private markets.
The Australian financial conglomerate said that, as part of the deal, it would collaborate with Nomura on product and distribution.
Macquarie has been strategically reshaping its North American operations, having already withdrawn from several debt market segments.
It is shuttering its US debt capital markets division, according to multiple media reports in February, pivoting instead to its private credit business, which has already deployed over A$22.5 billion (HK$112.36 billion) in loans.
"Overall, the transaction sharpens the focus of Macquarie Asset Management back to its competitive strengths - private markets and its home market of Australia," Citi analyst Thomas Strong wrote in a report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
a day ago
- South China Morning Post
Hong Kong Airlines to launch new direct routes to Melbourne and Lijiang
Hong Kong Airlines will roll out a new direct service to Melbourne and Lijiang in Yunnan province as part of an aggressive network expansion, with the carrier pledging to capitalise on the increased capacity of the city's international airport. The carrier said on Friday it would operate its direct service to Melbourne three times a week from December 12 using an Airbus A330 aircraft. The flight schedule will be flexibly timed to facilitate connections for passengers transiting through Hong Kong to popular destinations such as Vancouver, Bali, Tokyo and Osaka, it added. On Thursday, the company said it would launch the service between Hong Kong and Lijiang three times a week from September 8, using an Airbus A320 aircraft as the sole local carrier operating the route. Following the launch of services to Hulunbuir and Xi'an, Lijiang will become the airline's third new mainland China destination this year. 'This move aligns with the company's strategy to continuously develop its mainland China network and provide travellers with more diverse travel options,' it said. 'The new route … also facilitates convenient connections for transit passengers travelling on the airline's long-haul routes, such as Sydney and Vancouver, thereby strengthening Hong Kong's position as a leading international aviation hub.' Hong Kong Airlines' president Jeff Sun Jianfeng said the new destination of Melbourne would boost its Australian network following the resumption of its Gold Coast service in January and the launch of the Sydney route in June.
RTHK
a day ago
- RTHK
DSE candidates face 4pc rise in fees for 2026 exams
DSE candidates face 4pc rise in fees for 2026 exams The HKEAA says fees and charges are going up to optimise use of resources and maintain its long-term stability. File photo: RTHK The exams body on Friday announced a 4 percent increase in fees for the 2026 Hong Kong Diploma of Secondary Education (HKDSE) exams and the introduction of a new fees structure for private candidates. According to the Hong Kong Examinations and Assessment Authority (HKEAA), the fees for school candidates for key language and other subjects have been raised by HK$30 and HK$20 each respectively. For a candidate taking six subjects – two language and four other subjects – the total fees will amount to HK3,630. The HKEAA stated that the hike is similar to previous years and remains at a relatively moderate level, with the adjustment taking into account various factors. For private candidates, a flat fee of HK$595 will be charged and there will be a new two-tier fees structure depending on their residency status. Candidates who are non-Hong Kong permanent residents are required to pay HK$1,377 for each language subject and HK$1,119 for each additional subject, HK$600 more when compared with that for local residents. For non-permanent residents who are under 18 years old and sitting the exam for the first time, there will be a new special entry fee of HK$2,000 per person. That would mean examination fees of more than HK$9,800 for those taking four core subjects and two electives. The HKEAA said the fees and charges had been revised to optimise the use of resources and maintain the long-term financial stability of the body. "There has been a notable increase in the number of private candidates in recent years. Some of these candidates, holding non-HKDSE qualifications, are required to submit Special Entry applications, which necessitate substantial manpower and resources from the authority to carefully vet each case," it said. "Additional examination centres and personnel have also been arranged to accommodate the growing number of private candidates, further increasing the operational costs of the HKDSE."
South China Morning Post
2 days ago
- South China Morning Post
Pfizer, Chinese biotech firm 3SBio complete worldwide licensing deal for cancer drug
First announced in May, the deal will see 3SBio – based in Shenyang, capital of northeastern Liaoning province – receive a US$1.25 billion upfront payment from Pfizer for the exclusive right to sell its cancer drug, SSGJ-707, outside China. Under the terms of their agreement, Pfizer will also pay 3SBio up to US$150 million to solely develop and commercialise SSGJ-707 within the mainland, the two companies said on Thursday. Pfizer also agreed to buy 31.1 million new shares in S3Bio, or a 1.3 per cent equity stake, for HK$785 million, according to a stock exchange filing. The deal at HK$25.2055 per share represents a 17 per cent discount to its market price on Thursday. 3SBio's shares fell 6.41 per cent to HK$28.45 on Friday. The transaction reflected the strong momentum of Chinese biotech firms in the field of drugs research and the increased interest from major foreign pharmaceutical companies to license their intellectual property.
